Liver resection for metastases from breast cancer

Abstract

Background and Objectives: The value of liver resection for metastases from breast cancer is still controversial. This study was conducted to clarify safety and effectiveness of hepatectomy in this conditions and to identify selection criteria for patients suitable for liver resection. Methods: From January 1988 to December 2006, 39 patients underwent liver resection for metastases from breast cancer. The outcome of these 39 patients was retrospectively reviewed using a prospective database. Prognostic factors for patient survival were determined by univariate and multivariate analysis. Results: None of the patients died perioperatively and the morbidity rate was 13% (n ¼ 5). The overall 1-, 3-, and 5-year survival rates were 77%, 50%, and 42%, respectively. In the univariate analysis, metastatic manifestation prior to hepatectomy, vascular invasion and resection margin revealed statistically significant influence on survival. The multivariate analysis identified only resection margin as an independent prognostic factor for survival. Conclusions: Liver resection should be considered in the multimodal treatment approach of patients with metastatic breast cancer. Hepatic resection can be performed with low risk and offers a chance of long-term survival. Achievement of a curative resection and less important absence of previous metastatic manifestation represent suitable criteria to select patients for liver resection.

Liver resection and local ablation of breast cancer liver metastases – A systematic review

“…Size, site or number of BCLM were not generally found to be of significance, except that >1 BCLM was a negative factor in one study [23] (table 2). In the study by Elias [24], hormone receptor status was a positive factor, but this was refuted by several other studies [20,26,31,35]. In contrast, presence of hormone receptors in the primary BC as well as in BCLM had a negative influence in the study by Lubrano [36].…”

“…Presence of EHD had a negative effect in the studies by Sakamoto and Thelen [27,35], but was not significant in other studies [20,21,31].…”

“…Interval between primary BC and BCLM was a positive factor in the studies by Selzner, Pocard, and Caralt [20,22,37] but not so in several other studies [21,24,26,27,31,35,36]. Size, site or number of BCLM were not generally found to be of significance, except that >1 BCLM was a negative factor in one study [23] (table 2).…”

Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

“…Local treatments of liver metastases in breast cancer patients were evaluated in some studies in the literature. Microscopically complete (R0) resection of metastases were found to be a favorable prognostic factor in multiple studies reported in the literature [19][20] ; local ablation studies produced similar results with five year survival rates reaching up to 40%. 21 Performed in small prospective studies, it has been shown that RFA is also effective.…”

“…It has been reported that nearly 30% of breast cancer patients will develop liver metastases along the duration of their disease. 1-2 Liver metastases usually develop in the terminal stage of breast Hepatic with brain 13 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) International Journal of Hematology and Oncology cancer, and are often accompanied by extrahepatic metastases. Isolated liver metastases are very rare (4%-5%).…”